GeoVax Labs (NASDAQ:GOVX), Inc. (NASDAQ: GOVX) is a clinical-stage biotechnology company headquartered in Atlanta, Georgia, focused on the development of immunotherapeutics and vaccines for infectious diseases. The company’s proprietary Modified Vaccinia Ankara (MVA) vector platform drives its vaccine candidates, leveraging the ability of MVA to safely present antigens and stimulate robust immune responses. GeoVax’s pipeline includes vaccine programs targeting viral threats such as COVID-19, Zika, Ebola, and Lassa fever. Through preclinical and early-stage human clinical studies, the company seeks to demonstrate safety, immunogenicity, and protective efficacy in diverse populations.
At the core of GeoVax’s approach is the use of a two-component MVA prime and protein boost strategy. This heterologous prime-boost regimen is designed to amplify both cellular and humoral immunity, with the goal of delivering durable protection. GeoVax has advanced multiple candidates into Phase 1 and Phase 2 trials, collaborating with government agencies, academic institutions, and non-profit organizations. These partnerships support accelerated development timelines and bolster the company’s capacity to respond rapidly to emerging infectious disease threats.
Founded in the early 2000s, GeoVax has evolved its technology platform through successive generations of preclinical and clinical research. The company’s leadership team brings extensive expertise in virology, immunology, clinical development, and biomanufacturing. GeoVax is managed by seasoned executives and overseen by a board of directors with backgrounds in life sciences investment, regulatory affairs, and global health initiatives, positioning the firm to navigate the complex landscape of vaccine development.
GeoVax serves both domestic and international markets, with a focus on regions prone to outbreaks of vector-borne and emerging viral diseases. Its Atlanta facility houses research labs and manufacturing support, while strategic collaborations extend GeoVax’s reach into regions such as sub-Saharan Africa and South America. As the company advances its lead candidates through clinical milestones, it aims to address unmet medical needs and strengthen global preparedness against future pandemics.
